Treatment of anxiety disorders
暂无分享,去创建一个
D. Wedekind | B. Bandelow | Sophie Michaelis | Borwin Bandelow | Sophie Michaelis | Dirk Wedekind | Borwin Bandelow | Dirk Wedekind | B. Bandelow
[1] S. Hamilton,et al. Use of Antidepressants During Pregnancy?: What to Consider when Weighing Treatment with Antidepressants Against Untreated Depression , 2016, Maternal and Child Health Journal.
[2] H. Volz,et al. Efficacy of Silexan in mixed anxiety–depression – A randomized, placebo-controlled trial , 2016, European Neuropsychopharmacology.
[3] Hans Eriksson,et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial , 2011, International clinical psychopharmacology.
[4] Dan J Stein,et al. Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. , 2014, The Journal of clinical psychiatry.
[5] D. Baldwin,et al. Clinically relevant drug interactions in anxiety disorders , 2012, Human psychopharmacology.
[6] K. Dimopoulos,et al. Antidepressant use in pregnancy and the risk of cardiac defects. , 2014, The New England journal of medicine.
[7] H. Gross,et al. Use of benzodiazepines in anxiety disorders. , 1993, The New England journal of medicine.
[8] M. Hamilton. The assessment of anxiety states by rating. , 1959, The British journal of medical psychology.
[9] E. Rüther,et al. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. , 2000, Pharmacopsychiatry.
[10] F. Goodwin,et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. , 1993, Archives of general psychiatry.
[11] J. Strawn,et al. Pharmacologic Treatment of Pediatric Anxiety Disorders , 2016, Current Treatment Options in Psychiatry.
[12] B. Daniels,et al. Controlled Comparison of Computer-Aided Vicarious Exposure Versus Live Exposure in the Treatment of Spider Phobia , 2000 .
[13] P. Cuijpers,et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. , 2016, The lancet. Psychiatry.
[14] S. Cummings,et al. An Internet-Based Randomized, Placebo-Controlled Trial of Kava and Valerian for Anxiety and Insomnia , 2005, Medicine.
[15] Dan J Stein,et al. Efficacy of Agomelatine in Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled Study , 2008, Journal of clinical psychopharmacology.
[16] P. Schulz,et al. A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders. , 2008, Psychopharmacology bulletin.
[17] A. Serretti,et al. Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis , 2009, Journal of clinical psychopharmacology.
[18] W. Gaebel,et al. Erratum zu: Psychische Störungen in der Allgemeinbevölkerung. Studie zur Gesundheit Erwachsener in Deutschland und ihr Zusatzmodul „Psychische Gesundheit“ (DEGS1-MH) , 2015, Der Nervenarzt.
[19] T. Mackenzie,et al. Prevalence and treatment of mental disorders. , 2005, The New England journal of medicine.
[20] B. Bandelow,et al. Epidemiology of anxiety disorders in the 21st century , 2015, Dialogues in clinical neuroscience.
[21] J. Angst,et al. Social phobia. , 1995, European archives of psychiatry and clinical neuroscience.
[22] Dan J. Stein,et al. Pharmacotherapy for anxiety disorders in children and adolescents ( Review ) , 2022 .
[23] D. Stein,et al. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study , 2017, European Neuropsychopharmacology.
[24] K. Rickels,et al. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients , 1998, Psychological Medicine.
[25] M. Höfler,et al. [Mental disorders in the general population : Study on the health of adults in Germany and the additional module mental health (DEGS1-MH)]. , 2014, Der Nervenarzt.
[26] M. Iyo,et al. Cognitive Behavioral Therapy for Patients with Social Anxiety Disorder Who Remain Symptomatic following Antidepressant Treatment: A Randomized, Assessor-Blinded, Controlled Trial , 2016, Psychotherapy and Psychosomatics.
[27] J. Geddes,et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.
[28] J. Lindesay,et al. The Epidemiology of Depression and Anxiety , 2010 .
[29] A. Gumley,et al. Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland. , 2005, Health technology assessment.
[30] G. Rubio,et al. Generalized anxiety disorder: a 40‐year follow‐up study , 2007, Acta psychiatrica Scandinavica.
[31] A. Balkom,et al. Late-life Anxiety Disorders: A Review , 2011, Current psychiatry reports.
[32] D. Baldwin,et al. The separation of adult separation anxiety disorder , 2016, CNS Spectrums.
[33] L. Taylor,et al. St John's wort versus placebo in obsessive–compulsive disorder: results from a double-blind study , 2005, International clinical psychopharmacology.
[34] D. Smith,et al. Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxification setting and benzodiazepine-polydrug abuse. , 1990, Journal of psychiatric research.
[35] Olga V. Demler,et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.
[36] K. Manassis,et al. The use of medication in selective mutism: a systematic review , 2016, European Child & Adolescent Psychiatry.
[37] U. Lepola,et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. , 2003, The Journal of clinical psychiatry.
[38] Hans-Jürgen Möller,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[39] M. Beutel,et al. The German guidelines for the treatment of anxiety disorders , 2015, European Archives of Psychiatry and Clinical Neuroscience.
[40] P Tyrer,et al. Benzodiazepine Dependence , 1993, Drug safety.
[41] H. Möller,et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine. , 2014, The international journal of neuropsychopharmacology.
[42] R. Teschke,et al. Kava in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study , 2013, Journal of clinical psychopharmacology.
[43] S. Woods,et al. Early coadministration of clonazepam with sertraline for panic disorder. , 2001, Archives of general psychiatry.
[44] H. Möller,et al. DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 1: general aspects and paradigmatic discussion of depressive disorders , 2015, European Archives of Psychiatry and Clinical Neuroscience.
[45] S. Kennedy,et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study , 2004, International clinical psychopharmacology.
[46] J. López-Ibor,et al. What can be learnt from the natural history of anxiety disorders? , 2007, European Psychiatry.
[47] B. Penninx,et al. Adherence to evidence-based guidelines for depression and anxiety disorders is associated with recording of the diagnosis. , 2009, General hospital psychiatry.
[48] H. Eriksson,et al. A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder , 2011, Journal of clinical psychopharmacology.
[49] D. Brent,et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. , 2007, The American journal of psychiatry.
[50] R. Kessler,et al. 12‐Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project , 2004, Acta psychiatrica Scandinavica. Supplementum.
[51] S. Kellett,et al. Efficacy of Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults: Systematic Review, Meta-Analysis, and Meta-Regression. , 2016, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[52] M. Höfler,et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. , 2002, The Journal of clinical psychiatry.
[53] A. Gamma,et al. The generalized anxiety spectrum: prevalence, onset, course and outcome , 2009, European Archives of Psychiatry and Clinical Neuroscience.
[54] D. Greenblatt,et al. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. , 1990, Archives of general psychiatry.
[55] M. Beutel,et al. The diagnosis of and treatment recommendations for anxiety disorders. , 2014, Deutsches Arzteblatt international.
[56] J. Rosenbaum,et al. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. , 1993, The American journal of psychiatry.
[57] D. Wedekind,et al. A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[58] M. Lindquist,et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system , 1997, European Journal of Clinical Pharmacology.
[59] D. Stein,et al. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. , 2002, Archives of general psychiatry.
[60] Dan J Stein,et al. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database , 2009, Human psychopharmacology.
[61] K. Rickels. Benzodiazepines in the treatment of anxiety. , 1982, American journal of psychotherapy.
[62] J. Benjamin,et al. Double-blind placebo-controlled pilot study of paroxetine for specific phobia , 2000, Psychopharmacology.
[63] H. Möller,et al. The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice , 2016, European Archives of Psychiatry and Clinical Neuroscience.
[64] M. Schubert-Zsilavecz,et al. Comparison of German St. John's wort products according to hyperforin and total hypericin content. , 2001, Journal of the American Pharmaceutical Association.
[65] D. Wedekind,et al. Efficacy of treatments for anxiety disorders: a meta-analysis , 2015, International clinical psychopharmacology.
[66] R. Emsley,et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. , 2009, The Journal of clinical psychiatry.
[67] Georgina James,et al. Cognitive behavioural therapy for anxiety disorders in children and adolescents. , 2015, The Cochrane database of systematic reviews.
[68] J. Bobes,et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. , 2010, The international journal of neuropsychopharmacology.
[69] D. A. Spiegel. Psychological strategies for discontinuing benzodiazepine treatment. , 1999, Journal of clinical psychopharmacology.
[70] J. Davidson,et al. Kava in generalized anxiety disorder: three placebo-controlled trials , 2006, International clinical psychopharmacology.
[71] S. Kasper,et al. Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – A randomized, placebo-controlled trial , 2015, European Neuropsychopharmacology.
[72] J. McKenzie,et al. Newer generation antidepressants for depressive disorders in children and adolescents. , 2012, The Cochrane database of systematic reviews.
[73] D. Nutt,et al. Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics , 2016, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[74] Ø. Langsrud,et al. A randomized controlled trial of a home and school-based intervention for selective mutism - defocused communication and behavioural techniques. , 2014, Child and adolescent mental health.
[75] R. Kessler,et al. Twelve‐month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States , 2012, International journal of methods in psychiatric research.
[76] B. Bandelow. Comparison of the DSM–5 and ICD–10: panic and other anxiety disorders , 2017, CNS Spectrums.
[77] D. Baldwin,et al. The use of antidepressants in clinical practice: focus on agomelatine , 2010, Human psychopharmacology.
[78] Xiaogang Li,et al. The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis , 2016, Neuropsychiatric disease and treatment.
[79] Paul McCrone,et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology , 2014, Journal of psychopharmacology.
[80] J. Walkup,et al. Treatment of separation, generalized, and social anxiety disorders in youths. , 2014, The American journal of psychiatry.
[81] M. Boyle,et al. The use of waitlists as control conditions in anxiety disorders research. , 2016, Journal of psychiatric research.
[82] Olga V. Demler,et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.
[83] E. Rüther,et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. , 1998, The American journal of psychiatry.
[84] S. Stahl. Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. , 2002, The Journal of clinical psychiatry.
[85] Dan J Stein,et al. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. , 2012, The Journal of clinical psychiatry.
[86] H. Woelk,et al. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. , 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[87] G. Chouinard,et al. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. , 1999, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.
[88] S. Montgomery,et al. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. , 2005, The Journal of clinical psychiatry.
[89] Jordi Alonso,et al. Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). , 2007, The Journal of clinical psychiatry.
[90] R. Kessler,et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. , 1994, Archives of general psychiatry.
[91] Satish Iyengar,et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. , 2008, The New England journal of medicine.
[92] J. Bradwejn. Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions. , 1993, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[93] J. Mann,et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. , 2007, The American journal of psychiatry.
[94] D. Nutt,et al. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[95] J. Os,et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010 , 2011, European Neuropsychopharmacology.
[96] A. Scholey,et al. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence , 2011, European Neuropsychopharmacology.
[97] Harold Alan Pincus,et al. Prevalence and treatment of mental disorders, 1990 to 2003. , 2005, The New England journal of medicine.
[98] D. Baldwin,et al. Pregabalin for the treatment of generalized anxiety disorder: an update , 2013, Neuropsychiatric disease and treatment.
[99] F. Oyebode,et al. Psychotropics in pregnancy: safety and other considerations. , 2012, Pharmacology & therapeutics.
[100] H. Möller,et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care , 2012, International journal of psychiatry in clinical practice.
[101] V. Starcevic. The reappraisal of benzodiazepines in the treatment of anxiety and related disorders , 2014, Expert review of neurotherapeutics.
[102] J. Leite,et al. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo‐controlled pilot study , 2002, Phytotherapy research : PTR.
[103] D. Greenblatt,et al. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. , 1990, Archives of general psychiatry.
[104] J. Piacentini,et al. Integrated Behavior Therapy for Selective Mutism: a randomized controlled pilot study. , 2013, Behaviour research and therapy.
[105] J. Erickson,et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial , 2008, European Neuropsychopharmacology.